BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
Targeting molecular pathways of tumor growth has become a major focus of anti-cancer
treatments. This study aims to investigate the toxicity, pharmacokinetics, and preliminary
efficacy of the triplet combination of bevacizumab, RAD001, and panitumumab in patients with
refractory solid tumors.
This open-labeled, non-randomized phase I trial of bevacizumab, everolimus and panitumumab is
designed to assess the safety, tolerability and efficacy of this combination in adult
patients with advanced solid tumors.